AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$IDXX

Kingsley Lawrence D sold $1.2M of IDXX

Kingsley Lawrence D sold 2,203 shares of IDEXX LABORATORIES INC /DE (IDXX) at $532.08 ($1.17M total) on 2026-09-04.

Original reporting
SEC EDGAR · Kingsley Lawrence D
Published Sep 9, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IDXX
Bearish
medium confidence
Mentioned
$IDXX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDXXBearishLow
01

Why it matters

The director's sale reduces insider ownership, which may be interpreted as a bearish sign, but the amount is relatively small.

02

Market read

Insider sale news is relevant for short-term traders focusing on micro‑cap movements.

03

What to watch

Potential upcoming earnings or corporate actions not disclosed.

Relevance 6/10Novelty 6/10Timing: filing after market close on Sep 9, 2026

Background

Form 4 filings disclose insider transactions; traders monitor director sales for cues.

Company-level read

Ticker impact

$IDXXBearishMedium confidence
Context

Director Kingsley Lawrence D sold 2,203 shares of IDEXX Laboratories for $1.17 M, reducing his stake to 9,568 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

Sale size is modest relative to market cap, but director-level insider activity is closely watched by traders.

Market effects

Sector

Minimal impact on the broader diagnostics sector.

Regional

Limited to U.S. markets where IDEXX trades.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Company
    IDEXX Laboratories Inc.

    Provider of diagnostic and information technology solutions for animal health.

  • Individual
    Kingsley Lawrence D

    Director of IDEXX Laboratories.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IDXX insider trading history →

Related articles

SEP 5
$IDXXHighAI 8/10

Stronger Q2 Results And Raised 2026 Outlook Could Be A Game Changer For IDEXX Laboratories (IDXX)

IDEXX Laboratories (IDXX) reported Q2 2026 results exceeding earnings estimates, raising its full-year 2026 outlook. Key growth came from the Companion Animal Group, with improved margins. Management projects $5.7B revenue and $1.5B earnings by 2029, an 32% upside from current price. Analysts' views vary, with bearish estimates at $5.5B revenue and $1.5B earnings by 2029.

simplywall.st3 min
AUG 27
$IDXXHighAI 8/10

Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?

IDEXX Laboratories (IDXX), a global leader in animal health diagnostics, reported Q2 2026 revenue of $1.22B (up 9.7% YoY) and EPS of $4.07 (up 15.3%). The company raised its full-year outlook. Analysts have a 'Moderate Buy' consensus, with a mean price target of $718.14, suggesting 30.6% upside. IDXX stock is down 14.2% over 52 weeks, underperforming the S&P 500 and healthcare sector.

yahoo.com2 min
AUG 11
$IDXXHighAI 9/10

IDEXX (IDXX) Q2 2026 Earnings Call Transcript

IDEXX (IDXX) reported Q2 2026 results and an earnings call transcript. Premium instrument placements topped 5,200 units, including about 1,600 inVue Dx analyzers. Q2 EPS was $4.27. IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94, citing recurring revenue growth and margin expansion.

yahoo.com7 min